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ickle cell disease, a condition resulting from the 
inheritance of two abnormal Hb genes in which at Sleast one is the sickle haemoglobin, has become 
1one of the most important scourges of our time.
Sickle cell disease was first observed by Dr JB Herrick in 
1904 in the blood of an anaemic West Indian medical 
2student as described in a paper published in 1910.  
Thus the disease is occasionally called “Herrick's 
syndrome.” The disease was later named “Sickle cell 
3
anaemia” by Vernon Mason in 1922.  Since then giant 
strides have been made in our understanding and 




Malaria carries a high case fatality among patients with sickle cell disease. In Jos University Teaching Hospital, at the 
time of this study, the use of  Proguanil was the acceptable mode of chemoprophylaxis for preventing malaria in  
these patients.  Intermittent Preventive Treatment (IPT) with Sulphadoxine-Pyrimethamine [SP] has shown great 
potential for reducing the prevalence of malaria and anaemia among pregnant women, infants and travellers.  We 
hypothesised that monthly SP was superior to daily Proguanil in reducing malaria parasitaemia, clinical malaria 
attacks and sickle cell crises in such patients.
OBJECTIVE:
To assess the efficacy and affordability of monthly SP versus daily Proguanil for malaria chemoprophylaxis in patients 
attending Sickle Cell Clinic at Jos University Teaching Hospital, Plateau State, Nigeria.
Methods: One hundred and fifty four patients [114 children and 40 adults] with Sickle Cell Disease in their steady 
state were randomized to monthly SP or daily Proguanil for malaria chemoprophylaxis. Active detection of malaria 
parasite in the peripheral blood and packed cell volumes were done at each monthly visit to the clinic over a period 
of three months. The primary outcome measure was the proportion of patients with malaria parasite in the 
peripheral blood at the end of 3 months. The secondary outcome measures included episodes of clinical malaria 
attacks, frequency and type of sickle cell crises and adverse effects of the medication.
RESULTS: 
Ninety four percent [72/77] of patients in the SP group and 91% [70/77] in the Proguanil group respectively 
completed three months of follow up. SP reduced the prevalence of malaria parasitaemia by 25% [(14%) 10/72] 
2
compared to 6.4% [(30%) 21/70] in the proguanil group. [X  54; p = 0.01]. Seventeen percent [12/72] of the patients 
receiving monthly SP had malaria attacks compared to 57% [40/70] on prophylaxis with Proguanil. [X =25; p< 
0.0003]. Thirty three percent [24/72] of the patients receiving SP had at least an episode of bone pain crises 
2
compared to 69% [48/70] of the patients receiving Proguanil. [X  =17.6; p<0.0001]. SP was 8 times cheaper than 
Proguanil.
CONCLUSION: 
Monthly chemoprophylaxis with SP was more efficacious than daily Proguanil in reducing the prevalence of 
asymptomatic malaria parasitaemia, clinical malaria attack and sickle cell crises in patients with sickle cell disease. SP 
was 8 times cheaper than Proguanil. No significant side effect was recorded in both groups. The current practice of 
routinely prescribing daily Proguanil to SCD patients for malaria chemoprophylaxis needs to be reviewed.
Key Words: Sickle Cell Disease, Malaria Chemoprophylaxis, sickle cell crisis
2
Correspondence: Dr Madaki  JKA, 
Department of Family Medicine, Jos University Teaching Hospital. 
E-mail: wankarani62@gmail.com 
MONTHLY SULPHADOXINE-PYRIMETHAMINE COMBINATION 
VERSUS DAILY PROGUANIL FOR MALARIA CHEMOPROPHYLAXIS 
IN SICKLE CELL DISEASE: A RANDOMIZED CONTROLLED STUDY 
AT THE JOS UNIVERSITY TEACHING HOSPITAL.
1 2 1 3 1
4 2
Dawam JA, Madaki JKA, Gambazai AA, Okpe ES, Lar-ndam N,
Onu A, Gyang M.
1.
Department of Family Medicine, Jos University Teaching Hospital (JUTH) Jos, Plateau State, Nigeria.
2.
Department of Family Medicine,  University of Jos, Plateau State, Nigeria
3.
Department of Paediatrics, University of Jos, Plateau State, Nigeria
4.
Department of Family Medicine, Garki Hospital, Abuja, Nigeria
Original Article 
NigerJMed2016: 119-127
Copyright Ó 2016. Nigerian Journal of Medicine
Nigerian Journal of Medicine, Vol. 25 No. 2, April - June, 2016, ISSN 1115-2613
119
Nigeria in particular. It has been implicated in many 
cases of hyper-haemolytic anaemia.
Between 25 and 50% of fever among homozygous SCD 
patients in some part of Africa is caused by malaria, 
while about 20% of severe anaemia is also due to 
malaria.  
While it is agreed that the mortality and morbidity is 
increased in homozygous SCD individuals if they are 
infected with malaria, there is ample evidence that the S 
trait accounts for increased survival of children in early 
life in malaria endemic areas.  
This necessitates life long recommendation of malaria 
chemoprophylaxis for SCD individuals living in 
malaria endemic zones by health professionals.
Randomized, open label controlled studies to evaluate 
the effect of pyrimethamine versus proguanil in 
preventing malaria in children with sickle cell disease 
have shown that chemoprophylaxis against malaria is 
beneficial to sickle cell disease patients through 
reduction in the frequency of clinical malaria attacks, 
anaemia and other forms of sickle cell crises.
These studies also showed that both proguanil and 
pyrimethamine protect children with sickle cell disease 
from the complications of Plasmodium falciparum 
infection, despite persistent parasitaemia. The use of 
proguanil was more potent than pyrimethamine in 
preventing bone pain crisis in the same studies.             
The current practice is to give all affected individuals a 
daily dose of 1.5mg/kg of proguanil. Proguanil-
resistant strains of P. falciparum had been identified in 
Nigeria as far back as 1949.  It appears this has been on 
the increase leading to reduced effectiveness of 
proguanil prophylaxis.
A recent study conducted by Kitola et al in Ibadan, 
Nigeria and published in 2007 evaluated the 
prevalence of asymptomatic malaria parasitaemia in 
sickle cell disease patients. They found a prevalence of 
asymptomatic malaria parasitaemia to be 24% among 
sickle cell disease patients on malaria prophylaxis with 
proguanil which was the same prevalence amongst 
those not taking prophylaxis. Another study 
conducted in Enugu by Juwah AI et al found 17.4% 
prevalence of malaria parasitaemia among children 
presenting with anaemic crises even though they were 
on routine proguanil prophylaxis.  This suggest some 
degree of inadequate prophylaxis by proguanil at the 












The highest frequency of sickle cell disease remains in 
tropical regions, particularly sub-Saharan Africa, India 
and the Middle East. About 120,000 infants are born 
each year with sickle cell disease in Africa. The majority 
have sickle cell anaemia (Hb SS), but Hb SC and sickle 
cell β-thalassaemia (Hb S/B+ -thal) are also relatively 
4
common in West Africa.  
It has been reported that the prevalence of sickle cell 
disease (SCD) rises from the time of birth until about 
1
five years of age, after which there is no further change.   
This is because most of diagnoses of SCD are made 
before the age of 5 years.
It is estimated that in Nigeria alone, about 30,000 
children are born each year with sickle cell disease 
5
while one in 375 blacks in America has Hb SS.    The 
prevalence of SCD in Nigeria is about 3% of the 
population.  
Nigeria, with a population of about 140 million, is the 
most populous country in Africa. It has the largest 
concentration of patients with sickle cell disease in the 
whole world.
Malaria is one of the commonest precipitating factors in 
sickle cell disease crises in malaria endemic countries of 
sub-Saharan Africa and Southeast Asia.  
The prevention of malaria among those who are at high 
risk of death or serious morbidity such as pregnant 
women is practiced in many parts of the world where 
malaria is common.
One group at high risk of malaria is those with SCD and 
although malaria prevention is widely used among this 
group, there is little evidence base for the current 
practices in Nigeria.  
The increased mortality and morbidity among SCD 
individuals that are attributable to malaria are 
potentially preventable with available tools such as 
insecticide treated bed nets (ITNs), chemoprophylaxis 
and/ or intermittent preventive treatment (IPT).
SCD individuals can have crises precipitated by 
malaria and bacterial infections such as pneumococcus 
and Haemophilus influenzae, to which they are 
susceptible due to impaired immune function and 
functional asplenia. These factors are perhaps the most 
important ones in many developing countries where 
the S gene is highly prevalent.
Evidence suggests that malaria probably due to fever 
and dehydration is one of the most common cause of 
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Exclusion.
1.  Those with known history of hypersensitivity 
to sulphonamide group of drugs or proguanil.
2. Sickle cell disease patients with reported 
history or diagnoses of G- 6PD deficiency.
3. Sickle cell disease patients whose illness 
required admission.
Ethical consideration
An approval was obtained from the JUTH Ethical 
Committee and a signed consent was obtained from 
eligible consenting patients or care givers for subjects 
less than 18years.
Recruitment and allocation.
Consecutive patients attending the SCD clinics were 
assessed and those that met the study criteria were 
recruited and randomised into two groups. 
Randomisation was done using Open Epi generated 
random numbers which were placed separately in 
opaque envelopes. All patients picked numbers from 
these envelopes and those with odd numbers were 
allocated to a group while those with even numbers 
were allocated to the second group.  The 
randomisation was done in blocks of 30 for children 
and blocks of 10 for adults. The ratio of SCD patients 
seen on each clinic day in children and adult clinics was 
3:1 (60 versus 20) respectively which informed the 
decision of the investigator to recruit 3 children to 1 
adult. 
The participants were recruited over a month. The 
sickle cell clinic visits were every Wednesdays and 
Fridays for children and adult respectively.
Data collection.
Semi-structured, pre-tested questionnaires were 
administered to eligible consenting patients/parents at 
the beginning, during follow up and at the end of the 
study by the investigator. 
Information was collected on socio-demographic 
factors including the educational level of 
patient/parents, employment status, income of 
patient/parents (both parents), age at first diagnosis of 
sickle cell disease and symptoms that led to first 
diagnosis. Other documentation included study 
number, hospital number and age of patient, sex, 
telephone number of patient or parents in the case of 
children.
Further information was collected on frequency of 
crisis, type of crisis, the use and frequency of malaria 
prevention drugs, use of folic acid supplementation, 
use of untreated and insecticide treated bed nets, 
symptoms of malaria and tolerability of malaria 
prevention medication. Further information was 
Despite these earlier observations, no recent attempt 
has been made to evaluate the impact of a daily 
regimen of proguanil on compliance, affordability and 
efficacy.
The long-term use of malaria chemoprophylaxis by 
sickle cell disease patients confers loss of immunity to 
malaria; hence the consequence of non-compliance 
may be as grave as that of acute severe Plasmodium 
falciparum infection and its complications.                                                                                                        
With the increasing incidence of chloroquine resistant 
strains of plasmodium species, chemoprophylaxis with 
chloroquine is no longer advisable.  
Sulphadoxine-pyrimethamine (SP) combination for 
malaria chemoprophylaxis has been shown to be 
effective and more potent in pregnant women, 
travellers, under five children and infants.
A randomised double blinded controlled trial by 
Nakibuuka V, et al carried out in Uganda and 
published in 2010 showed that SP reduced prevalence 
of malaria by 50% compared to chloroquine. Six 
percent (7/122) of the children receiving weekly 
chloroquine had malaria related admissions compared 
to 2.5% (3/120) on presumptive treatment with SP. 
There were no serious drug site effects reported in both 
treatment groups.
There are no published studies in Nigeria evaluating 
the efficacy, compliance, affordability and the 
tolerability of this drug in sickle cell patients. Its single 
monthly dosing may promote adherence as well as 
reduce cost and the pill burden on sickle cell disease 
patients. 
Presently, one month adult course of daily proguanil 
(200mg)  cost about  six hundred Naira (N 600 ), while 
an adult dose of SP cost between  thirty and seventy 
Naira (N 30 - N 70 ) per month depending on the brand.
METHODS.
This study was carried out at the Jos University 
Teaching Hospital [JUTH] which is a 525 bed hospital. 
It offers primary, secondary and tertiary medical 
services to Plateau state and the neighbouring states.
The study was carried out between August and 
December 2009. It was commenced at the peak of the 
rainy season when malaria transmission was high.
One hundred and fifty four patients [114 children and 
40 adults] with Sickle Cell patients were needed to 
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Students''t' test was used to compare the mean values 
of PCV, PCV change, mean temperature, mean weight 
and mean height in the two groups.  Univariate 
analyses was used to determine the influence of parents 
income/mother's educational level, the use of 
insecticide treated bed nets, and the two interventions 
on risk of asymptomatic parasitaemia, clinical malaria 
attacks and frequency of crises. p< 0.05 was considered 
statistically significant.
RESULTS.
Ninety four percent [72/77] of patients in the SP group 
and 91% [70/77] in the Proguanil group respectively 
completed three months of follow up.  Table 2 shows 
that the prevalence of asymptomatic malaria 
parasitaemia was 37.7% (58/154) at recruitment [30 
patients (39%) from the SP arm and 28 patients (36.4%) 
from the proguanil arm].  
Figure 3 shows that 16.7% (12/72) of participants in the 
intervention group had at least 1 episode of clinical 
malaria attack compared to 57.1% (40/70) of 
participants in the control group (Chi-square 25.1); 
P<0.0003.  At the end of the study, 33.3% (24/72) of the 
participants had at least one episode of bone pain crises 
in the intervention group compared to 68.6% (48/70) 
participants in the control group (chi-square 17.6); 
p<0.0001(figure 4)
The mean packed cell volume (PCV) of the control 
group and the intervention groups at recruitment were 
22.96 ± 3% and 23.0 ± 2% respectively. At the end of the 
study, the mean PCV was 23.1 ± 3% and 24.0 ± 2.9% in 
the control and intervention groups respectively. ('t' 
test = 1.9); P-value = 0.29. The PCV range was 16-38% 
(table 3).
Although there was a statistically significant increase 
in mean PCV change (PCV 3 months-PCV day1) in both 
study groups at the end of the study,  there was no 
statistically significant change in the mean PCV 
between the two groups (table 4).
The average cost of purchasing malaria prevention 
drugs was fifty eight naira (N58.00) per person for a 
month in the intervention group (N7.50k- N100.00k), 
and four hundred and fifty naira (N450.00) per person 
for a month in the control group (N150.00k-
N750.00k).This means that proguanil was 8 times more 
expensive than SP.
Discussion 
There was a 25% reduction in malaria parasitaemia in 
the peripheral blood in the intervention group [14% 
(10/72)] compared to 6.4% in the control [30% (21/70)], 
Chi-square=54; p=0.01
collected on body temperature, weight, height, packed 
cell volume, malaria parasite and splenic size.
Group health talks on the importance of adhering to 
prophylactic medications, the use of insecticide-treated 
bed nets and environmental sanitations were given to 
patients and their relations that accompanied them to 
the hospital. This was re-enforced at the time of 
administering the questionnaire and at each follow up 
visit.
Each patient was then sent to an intern pharmacist for 
his/her folic acid and malaria prevention drug before 
seeing their managing Physician who only prescribes 
any additional treatment the patient may need. These 
procedures were repeated at each follow up visit which 
was every 4 weeks for three months. 
3.2.0. Interventions.
Eligible consenting patients were randomised to:  
1) Monthly sulphadoxine-pyrimethamine 
(experimental) arm.
 2) Daily proguanil (control) arm.
Treatment allocations was prepared in a series of 
opaque envelopes and administered by a third party 
(the Pharmacist).
The investigator was blinded on which drug each 
patient was taking until data collection was completed.
Adherence to medication was ensured by patient 
swallowing their monthly medication in the presence 
of the pharmacist [SP group], the same applies to the 
first dose of proguanil. Further adherence to proguanil 
was evaluated by checking the pill boxes of patients 
during their next follow up visits.  Children who could 
not swallow tablets were administered crushed tablets 
dissolved in clean water.    
Drug dosages.
1. Daily proguanil (1.5mg/kg) to a maximum of 
2 0 0 m g  ( m a n u f a c t u r e d  b y  M a n c a r e  
Pharmaceuticals).
2. Monthly sulphadoxine-pyrimethamine at 
dosages of 25mg/kg of sulphadoxine and 
1.25mg/kg of pyrimethamine manufactured 
by Swipha (up to a maximum dose of 3 
tablets).
Statistical methods.
Data was analysed after it was entered into Epi info 
version 3.5.1 (CDC, Atlanta, Georgia, USA.).  Analysis 
was by intention to treat.  Chi-square was used to 
compare the proportions of patients with 
asymptomatic parasitaemia, acute clinical malaria 
attacks and frequency of sickle cell crisis in the two 
groups. 
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intervention group and the control group at the end of 
12 weeks (23.1 ± 3% versus 24.0 ± 2.9%, p = 0.97). This is 
probably due to the anti- folate activity of both drugs.
Although forgetfulness rather than cost was the major 
reason for poor adherence to proguanil in this study, 
the cost of proguanil per person per month was about 
eight (8) times that of SP (N58.00k for SP versus 
N450.00k for proguanil). In Nigeria where poverty is 
endemic, a less expensive but effective drug like SP will 
be of economic advantage in reducing the financial 
burden of these patients and their family.
In addition to the potential to reduce the financial 
burden of most families with SCD patients, SP as a 
monthly medication can reduce the problem of 
adherence to malaria prevention drugs in sickle cell 
disease patients. Adherence could further be 
strengthened by making the administration of this 
drug a form of directly observed therapy (DOT) in a 
four weekly follow up visit.
Conclusion
SP prophylaxis in SCD has demonstrated superior 
efficacy and similar tolerability compared to Proguanil 
by significantly reducing the prevalence of malaria 
parasitaemia, episodes of clinical malaria attacks and 
much of SCD crises. SP is 8 times cheaper than 
Proguanil. No significant side effect was recorded in 
both groups.
This study has shown that adherence is very poor with 
a daily malaria prevention drug like Proguanil, 
however this can be improved by giving adherence 
counselling at each clinic visit as was done in this study 
(adherence improved from 16% at base line to 98% at 
the end of the study).  
There was no significant change in the mean packed 
cell volume and drug side effects between the groups.
Competing Interest:  we the authors hereby declare 
that we have no competing interest.
This is similar to the result of Nakibuuka et al from 
Uganda, even though their study compared weekly 
chloroquine and monthly SP for malaria prophylaxis in 
sickle cell disease patients.
Although there was 6.4% drop in the prevalence of 
asymptomatic malaria from the base line in the 
Proguanil group, this could be attributed to the 
adherence counselling given to all patients at 
recruitment and follow up visits. Adherence was 
further re-enforced by counting the pill boxes at 
subsequent follow up visits for the Proguanil group 
which improved the adherence from 16% at base line to 
about 98% at the end of the study although it was not 
possible to ascertain whether they were really taking 
the drug or just bringing empty pill boxes to the clinics.
There was a statistically significant reduction in the 
episodes of sickle cell disease crises in the intervention 
group (33%) as compared to the control group (69%). 
Chi-square=17.6; p<0.0001.
There was also 41% reduction in the episodes of clinical 
malaria attack in the intervention group (16%) 
compared to the control group (57%). Chi-square=25; 
P<0.0003, which was statistically significant.  These 
findings are similar to the 40% reduction in malaria 
attacks by SP compared to chloroquine documented by 
22
Nakibuuka et al in Uganda.  
This difference in efficacy between the two drugs could 
be explained by the fact that resistance to prophylactic 
dose of proguanil is higher probably due to poor 
adherence  compared to SP.
The other reason is that SP has a longer half life and its 
terminal elimination phase normally exceeds the 
minimum parasiticidal concentrations which is the 
lowest concentrations that give maximum effect].   In 
contrast this does not occur in proguanil.
While SP may have failed as a mono therapeutic agent, 
it is still effective for prophylaxis. Several studies from 
Nigeria, Ghana, Mozambique and Tanzania have 
documented its usefulness in prophylaxis and 
particularly in reducing malaria episodes even in areas 
where resistance is high.
There was a statistically significant increase in mean 
PCV change (PCV 3 months-PCV day1) in both study 
groups at the end of the study. This could be due to the 
reduction in malaria parasitaemia documented in the 
two groups at the end of this study probably due to 
improved adherence mentioned earlier.  
There was no statistically significant change in the 
mean packed cell volume (PCV) between the 
22
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Table 1:  Physical and Socio-demographic characteristics of participants at recruitment  
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Table.2.  Laboratory characteristics of patients at recruitment
Variable  SP  proguanil  p value
MP  
      
positive
 
       
Negative
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Figure 4
Table 3. Mean PCV of patients in the 2 groups at recruitment, follow up and 3 months.
Mean PCV  SP   Proguanil  
Day1















Table 4.  Mean PCV change (PCV 3 months -  PCV day1) in the two groups  
 Mean PCV 
difference
 
















* paired ‘T’ test.
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